Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban

This article was originally published in The Pink Sheet Daily

Executive Summary

Unable to find a partner to co-develop the compound, Astellas is bowing out of the anticoagulant space.

You may also be interested in...

For Merck, Outcomes Trials Offer Fast Track To Payers

More so than any other big pharma, Merck is dependent on large outcomes trials. The cost of failure is high, but success would allow entry into massive, highly generic primary care markets with products backed by clinical outcomes data that meet payers’ need for real-world evidence of a drug’s value in terms of health economics as well as clinical efficacy.

Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding

Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.

Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing

TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts